A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-04 and is reviewed periodically as new material appears.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Polymyxins are antibiotics. Polymyxins B and E (also known as colistin) are used in the treatment of Gram-negative bacterial infections. They work mostly by breaking up the bacterial cell membrane. They are part of a broader class of molecules called nonribosomal peptides. They are produced in nature by Gram-positive bacteria such as Paenibacillus polymyxa.
Food and Drug Administration (FDA) does not approve bromide for the treatment of any disease, and sodium bromide was removed from over-the-counter (OTC) sedative products like Bromo-Seltzer, in 1975. FDA banned organic bromides from OTC sleep aids in 1989. Commercially available organobromine pharmaceuticals include the vasodilator nicergoline, the sedative brotizolam, the anticancer agent pipobroman, and the antiseptic merbromin. Otherwise, organobromine compounds are rarely pharmaceutically useful, in contrast to the situation for organofluorine compounds. Several drugs are produced as the bromide (or equivalents, hydrobromide) salts, but in such cases bromide serves as an innocuous counterion of no biological significance. Organobromine compounds are used as psychedelic and designer drugs such as 2C-B, Bromo-DragonFLY, and 4-Bromomethcathinone. Other uses of organobromine compounds include high-density drilling fluids, dyes (such as Tyrian purple and the indicator bromothymol blue), and pharmaceuticals. Bromine itself, as well as some of its compounds, are used in water treatment, and is the precursor of a variety of inorganic compounds with an enormous number of applications (e.g. silver bromide for photography). Zinc–bromine batteries are hybrid flow batteries used for stationary electrical power backup and storage; from household scale to industrial scale. Bromine is used in cooling towers (in place of chlorine) for controlling bacteria, algae, fungi, and zebra mussels.
=== Pharmacodynamics === Etilefrine is an agonist of the α1-adrenergic receptor. It is a vasoconstrictor and antihypotensive agent. It has also been described as a β1-adrenergic receptor agonist with some agonistic actions at the α- and β2-adrenergic receptors. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return, and blood pressure in humans and animals, suggesting stimulation of both α- and β-adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β1 (cardiac) than for β2 adrenoreceptors. Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure, and mean arterial pressure of healthy individuals. Peripheral vascular resistance falls during the infusion of 1 to 8 mg etilefrine but begins to rise at higher dosage. Marked falls in pulse rate, cardiac output, stroke volume, and peripheral blood flow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2.5 mg. These findings indicate that etilefrine has both β1- and α1-adrenergic receptor actions in humans.
Ochronosis is a medical condition characterized by the accumulation of homogentisic acid in connective tissues, leading to pigmentation changes. The term derives from the yellowish-brown (ocher-like) discoloration observed in histological samples. However, macroscopically, the affected tissues often appear bluish-grey due to the Tyndall effect, a phenomenon in which scattered light gives deeper-lying pigments a blue hue. Ochronosis is most commonly associated with the rare metabolic disorder alkaptonuria, a genetic condition involving homogentisic acid oxidase deficiency. It may also occur as an acquired condition, known as exogenous ochronosis, resulting from prolonged topical application or systemic exposure to certain phenol derivatives, particularly hydroquinone. The condition was first described by German pathologist Rudolf Virchow in 1865.
== External links == Sir Howard Florey on Nobelprize.org including the Nobel Lecture, "Penicillin", 11 December 1945 Oral History: Sir Howard Florey—Interviewed by Hazel de Berg in 1967 (audio recording)
Sources: en.wikipedia.org
=== Naming === Using Mendeleev's nomenclature for unnamed and undiscovered elements, darmstadtium should be known as eka-platinum. In 1979, IUPAC published recommendations according to which the element was to be called ununnilium (with the corresponding symbol of Uun), a systematic element name as a placeholder, until the element was discovered (and the discovery then confirmed) and a permanent name was decided on. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who called it "element 110", with the symbol of E110, (110) or even simply 110. In 1996, the Russian team proposed the name becquerelium after Henri Becquerel. The American team in 1997 proposed the name hahnium after Otto Hahn (previously this name had been used for element 105). The name darmstadtium (Ds) was suggested by the GSI team in honor of the city of Darmstadt, where the element was discovered. The GSI team originally also considered naming the element wixhausium, after the suburb of Darmstadt known as Wixhausen where the element was discovered, but eventually decided on darmstadtium. Policium had also been proposed as a joke due to the emergency telephone number in Germany being 1–1–0. The new name darmstadtium was officially recommended by IUPAC on August 16, 2003.
== Interpretation == One study reviewed the relative diagnostic value of enzyme and bicarbonate concentrations compared with enzyme output in 363 secretin-CCK tests. The investigators also evaluated the requirement for perfusion markers to accurately quantify volume, and the validity of a shortened sampling time (first 20 minutes). Only 60 percent of volume was recovered with the duodenal aspiration tube, suggesting that marker perfusion to correct for distal loss of secretion is important to accurately quantify volume. Using a trypsin output <50 U/kg/h as the reference standard, measurement of enzyme concentration alone misclassified approximately 10 percent of patients. Use of a shortened collection time misclassified approximately 4 percent of patients. The authors concluded that this was an unacceptably high rate of misclassification and that the standard prolonged collection of fluid using a perfusion marker must be performed to accurately measure exocrine function.
== Treatment == For people with the FOLR1 mutation, even when the systemic deficiency is corrected by folate (the oxidized form - folic acid), the cerebral deficiency remains, and must be treated with folinic acid. Folinic acid is a metabolically active form of folate that can be easily introduced into the folate cycle. A typical dose that is administered to children is 0.5–1 mg/kg daily, but the dose can be increased depending on the severity of symptoms and the age of the child. Over time, the treatment with folinic acid has shown to reduce a variety of symptoms of CFD. The treatment of folinic acid can lead to improvements in walking, speech, interpersonal skills and reduction in seizures. Success depends on early initiation of treatment. Starting the folinic acid treatment before the age of six is more advantageous for the child with CFD. If the treatment is started after the age of six, its results are not as effective. Treatment requires taking folinic acid for lengthy periods. Fewer than 20 people with the FOLR1 defect have been described in the medical literature. Folinic acid (5-formyl-THF, 5-fTHF) also appears useful for some other forms of CFD. Pharmacologic doses of folinic acid has also led to reversal of some symptoms in children diagnosed with cerebral folate deficiency and testing positive for autoantibodies to folate receptor alpha. It also appears useful in DHFR deficiency and AADC deficiency. 5-MTHF (5-methyl-THF) is also available as a drug (levomefolic acid). It is "thought to be the most efficient way to restore CSF 5-MTHF concentrations".
Mycoplasma pneumoniae Chlamydia pneumoniae Hepatitis B virus (HBV) Parvovirus B19 Adenovirus (ADV) Respiratory syncytial virus (RSV) The immune cell involvement in polymyalgia rheumatica includes the activation of dendritic cells and monocytes/macrophages, leading to inflammation in the synovium and bursae of the shoulder and hip girdles which is primarily mediated by the innate immune system. There is an altered balance between Th17 and Treg cells, with increased IL-6 levels driving Th17 cell activation. Disturbed B cell distribution and function are also observed, with a decrease in circulating B cells that recover after steroid treatment. Additionally, systemic activation of circulating monocytes is associated with increased IL-6 and IL-1 beta production. Associations of uncertain significance with multiple types of TNF have also been found. Despite the severe pain associated with the condition in multiple muscle groups, as well as the signs of systemic inflammation, muscle biopsies have found no signs of localized inflammation in muscle tissue in patients with PMR. Electromyography studies also typically turn up normal. The only locations known definitively to be inflamed in PMR are the synovial membranes and bursae of joints. Persons having the HLA-DR4 type of human leucocyte antigen appear to have a higher risk of PMR.
Muscle biopsy (removes a small piece of muscle tissue, usually from the thigh, to check for dystrophin in muscle cells.) Creatine kinase test (checks the level of Creatine Kinase proteins in the blood. Creatine Kinase proteins are normally found inside of healthy muscle cells, but can be found in the blood when muscle cells are damaged.) Electromyography (shows that weakness is caused by the destruction of muscle tissue rather than by damage to nerves.) Genetic testing (looks for deletion, duplication, or mutation of the dystrophin gene.)
Sources: en.wikipedia.org
The Parliament of Malaysia consists of the Yang di-Pertuan Agong (King) and two houses, the Dewan Rakyat (the House of Representatives) and Dewan Negara (the Senate). The term "members of Parliament" only refers to members of the Dewan Rakyat. In Malay, a member of Parliament is called Ahli Parlimen, or less formally wakil rakyat (people's representative). Members of Parliament are elected from population-based single-seat constituencies using first-past-the-post voting. The prime minister must be a member of Parliament. Members of Parliament are styled Yang Berhormat ("Honourable") with the initials Y.B. appended prenominally. A prince who is a member of Parliament is styled Yang Berhormat Mulia. The prime minister, deputy prime minister and Tuns who are members of Parliament are styled Yang Amat Berhormat ("Most Honourable"), abbreviated Y.A.B.
== Epidemiology == SJS is a rare condition, with a reported incidence of around 2.6 to 6.1 cases per million people per year. In the United States, about 300 new diagnoses are made each year. The condition is more common in adults than in children.
== Diseases and disorders == The following sections describe how imbalances or dysfunction in specific neurotransmitters—dopamine, serotonin, and glutamate—have been tentatively linked to various mental or neurological disorders.
Since 1921, the Toronto Transit Commission (TTC) gradually expanded its public transportation network to Scarborough. Today, it operates bus and rapid transit routes in the district. Line 2 Bloor–Danforth has three subway stations in Scarborough: Victoria Park, Warden, and Kennedy, the current eastern terminus. In 1985, the Government of Ontario opened the Scarborough RT, an above-ground light metro line that operated between Kennedy station at its west and McCowan Road at its east. In 2023, the line shut down permanently due to aging Infrastructure which also caused a derailment earlier that year. Construction of an extension of Line 2 further east into Scarborough started in June 2021 and is expected to be complete around 2030. The line will be extended 7.8 kilometres from Kennedy station with stations at McCowan Road-Lawrence Avenue, Scarborough Centre, and McCowan Road-Sheppard Avenue. Opened in February 2026, Line 5 Eglinton is a light rail line with its eastern terminus at Kennedy station. The City of Toronto is also proposing another light rail line known as the Eglinton East LRT that is planned to operate from Kennedy station to the University of Toronto Scarborough. Seven rail stations also provide access to two commuter rail lines operated by GO Transit. The Lakeshore East line runs across the south end of the district with Rouge Hill GO Station, Guildwood GO Station, Eglinton GO Station, and Scarborough GO Station running from east to west.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.